Ulcerative colitis (UC) is one of the inflammatory bowel diseases (IBD). It is a chronic autoimmune inflammation of unclear etiology affecting the colon and rectum, characterized by unpredictable exacerbation and remission phases. Conventional treatment options for UC include mesalamine, glucocorticoids, immunosuppressants, and biologics. The management of UC is challenging, and other therapeutic options are constantly being sought. In recent years more attention is being paid to curcumin, a main active polyphenol found in the turmeric root, which has numerous beneficial effects in the human body, including anti-inflammatory, anticarcinogenic, and antioxidative properties targeting several cellular pathways and making an impact on intestinal microbiota. This review will summarize the current knowledge on the role of curcumin in the UC therapy.
Strengths
Section 5 summarizes five systematic reviews and meta-analyses with key effect statistics and a clear comparison table, and explicitly cites the overview finding that all assessed reviews were of very low methodological quality.
↳ Section 5, pp. 5-6; Table 1, p. 6
The pediatric section assembles ECCO/ESPGHAN induction and maintenance dosing into a single accessible table, a clinically useful focus not always present in adult-oriented reviews.
↳ Section 6, p. 6; Table 2, p. 7
Complex pharmacokinetic and mechanistic content is explained at a level appropriate for a clinical readership, and the structure flows logically from biological rationale to clinical implications.
↳ Sections 1-6, pp. 1-7
Limitations
The review cites the overview finding that the underlying systematic reviews are of very low methodological quality but does not use it to calibrate its overall optimistic framing, leaving the conclusions more confident than the evidence supports.
↳ Section 5, p. 6; Section 7, p. 7
The microbiota discussion rests on one healthy-volunteer study and two animal models, with the authors acknowledging that no human studies of curcumin on the gut microbiome in UC patients have been published.
↳ Section 4, pp. 4-5
As a narrative review the paper provides no formal search strategy, inclusion criteria, or declared reporting standard, and limitations are confined to a brief mention in the conclusion, reducing transparency about scope and selection.
↳ Section 5, p. 5; Section 7, p. 7
The adjudicated scores reflect a competently written but descriptive review whose central limitation is that it consolidates rather than critically appraises an evidence base it itself reports as methodologically very low. Evaluations converged on clear structure and accessible exposition (Sections 1-6) and on the modest, integrative nature of the contribution, while diverging mainly on how much credit the breadth of literature engagement and the existing ECCO/ESPGHAN guideline linkage (Section 6) deserve relative to the non-transparent selection basis and un-integrated quality caveat (Section 5, p. 6). The Positioning score settled at the convergent middle because the paper genuinely engages prior meta-analyses yet does not let the very-low-quality finding shape its conclusions. On impact, the existing guideline mention and active research trajectory support real but bounded relevance, while the small, heterogeneous underlying trials cap translation and transferability. The framing that presents curcumin more favorably than the mixed evidence warrants underlies the Amber reliability picture without overturning the core descriptive message.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.0
Confidence highThe review competently collates recent systematic reviews and meta-analyses plus guideline-oriented pediatric dosing context, but offers no novel framework, original meta-analysis, or critical synthesis beyond what the cited reviews already provide. Its most distinctive element is the consolidated pediatric ECCO/ESPGHAN dosing content.
This review will summarize the current knowledge on the role of curcumin in the UC therapy.
The paper is clearly structured from pharmacology through mechanism, microbiota, clinical evidence, and pediatric dosing, but functions as sequential topic summaries rather than a developed argument, with evidence marshalling that favors supportive findings and no formal search method. It does surface the overview finding that prior reviews are of very low methodological quality.
They found the methodological quality of all assessed SRs/Mas to be very low.
The article is logically organized and accessible to a clinical readership, with technical pharmacokinetic and NF-kB content explained at an appropriate level and useful summary tables. A minor tone mismatch exists between the more optimistic abstract framing and the hedged body conclusions.
numerous beneficial effects in the human body
The paper engages a substantial prior literature including multiple meta-analyses and ECCO/ESPGHAN guidance and explicitly cites the overview rating the supporting reviews as very low quality, but does not use that caveat to calibrate its conclusions, declare a reporting standard, or examine the underlying RCT quality. The selection basis for a narrative review is not transparent.
curcumin may be effective and safe for treatment of UC, but that further research is needed
Lower confidence on Methodological Rigour, Positioning — domain match limited.
Caveats3 of 4 checks
The review is internally readable and consistent in its central message, and Table 1 matches the text descriptions of the cited reviews. However, the abstract and conclusion framing of curcumin as a promising adjunct runs somewhat ahead of the heterogeneous, low-quality evidence base the paper itself acknowledges, and the synthesis foregrounds positive systematic reviews over null or quality-limiting findings.
No conduct problem material for a narrative review: conflicts of interest are declared as none, funding is declared as none, and ethics is appropriately marked not applicable. The only watch-out is a data availability statement that is effectively non-informative for a literature review with no primary dataset.
Flags: 3 declared / 5 total
Not yet checked.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
The evidence is beyond basic observation given existing RCTs, meta-analyses, and guideline mentions, but is not deployment-ready: optimal dose, formulation, and delivery remain unresolved and the underlying review evidence is independently rated very low quality. A clinician could not confidently prescribe on this synthesis alone.
Well-planned, large-scale, randomized controlled trials are needed
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Ben-Horin, Salomon, Karampekos, et al. · 2023 · Clinical medicine
Sadeghi, Mansoori, Shayesteh, et al. · 2019 · Clinical medicine
Zhang, Chen, Chen, et al. · 2025 · Basic medicine